Want to see BLLN full AI Analyst Report?
BLLN Stock Chart & Stats
$139.59
-$0.99(-0.71%)
At close: 4:00 PM EDT
$139.59
-$0.99(-0.71%)
Day’s Range― - ―
52-Week Range$61.96 - $140.21
Previous Close$138.3
Volume531.14K
Average Volume (3M)678.97K
Market Cap
$6.42B
Enterprise Value$3.79K
Total Cash (Recent Filing)$537.45M
Total Debt (Recent Filing)$144.19M
Price to Earnings (P/E)269.3
Beta1.06
Next Earnings
Aug 05, 2026EPS Estimate
0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.51
Shares Outstanding41,442,833
10 Day Avg. Volume580,370
30 Day Avg. Volume678,966
Financial Highlights & Ratios
PEG Ratio-12.02
Price to Book (P/B)7.81
Price to Sales (P/S)12.29
P/FCF Ratio238.56
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$129.50Price Target Upside-7.23% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)0.98
Revenue Forecast (FY)$455.96M
Bulls Say, Bears Say
Bulls Say
Raised 2026 Revenue GuidanceManagement raised full‑year 2026 revenue guidance to $445–$465M (48%–52% growth) driven mainly by higher ASPs. This reflects durable pricing power from new payer contracts and a larger revenue base, improving visibility for multi‑quarter planning and investment allocation.
Material Margin Expansion And Unit EconomicsASP expansion and a 73% gross margin indicate materially improved unit economics driven by higher pricing and mix (prenatal strength). Higher, sustainable gross margins increase leverage to operating‑income as volumes scale and reduce sensitivity to modest cost fluctuations over the medium term.
De‑risked Balance Sheet And Cash GenerationA large cash buffer (~$537M), positive operating cash flow and much lower leverage (debt/equity ~0.23x) materially improve financial flexibility. That balance sheet strength supports capex, lab expansion, and R&D investments without near‑term refinancing risk, enabling strategic execution.
Bears Say
Oncology Reimbursement DependenceOncology margins are currently subscale and hinge on Medicare coverage for NorthStar Response. Reimbursement decisions are multi‑quarter regulatory processes; delays or limited coverage would durably depress oncology ASPs and margins as volumes scale, pressuring consolidated profitability.
Revenue Recognition And AR Timing VolatilityTrue‑ups and large new payer contracts have increased AR and introduced recognition timing risk. This can create recurring quarter‑level volatility in reported revenue and cash collection, complicating cash‑flow forecasting and working capital management across multiple reporting periods.
Low Returns And Noisy Cash‑conversionAlthough profitability turned positive, ROE (~1.6%) and net margins remain thin, and free‑cash‑flow growth has been volatile. Persistently low returns and inconsistent cash‑conversion metrics could limit shareholder returns and make sustained margin expansion necessary to justify growth investments over the medium term.
BillionToOne, Inc. Class A News
BLLN FAQ
What was BillionToOne, Inc. Class A’s price range in the past 12 months?
BillionToOne, Inc. Class A lowest stock price was $61.96 and its highest was $140.21 in the past 12 months.
What is BillionToOne, Inc. Class A’s market cap?
BillionToOne, Inc. Class A’s market cap is $6.42B.
When is BillionToOne, Inc. Class A’s upcoming earnings report date?
BillionToOne, Inc. Class A’s upcoming earnings report date is Aug 05, 2026 which is in 3 days.
How were BillionToOne, Inc. Class A’s earnings last quarter?
BillionToOne, Inc. Class A released its earnings results on May 06, 2026. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.031 by $0.309.
Is BillionToOne, Inc. Class A overvalued?
According to Wall Street analysts BillionToOne, Inc. Class A’s price is currently Overvalued.
Does BillionToOne, Inc. Class A pay dividends?
BillionToOne, Inc. Class A does not currently pay dividends.
What is BillionToOne, Inc. Class A’s EPS estimate?
BillionToOne, Inc. Class A’s EPS estimate is 0.18.
How many shares outstanding does BillionToOne, Inc. Class A have?
BillionToOne, Inc. Class A has 41,442,833 shares outstanding.
What happened to BillionToOne, Inc. Class A’s price movement after its last earnings report?
BillionToOne, Inc. Class A reported an EPS of $0.34 in its last earnings report, beating expectations of $0.031. Following the earnings report the stock price went up 14.128%.
Which hedge fund is a major shareholder of BillionToOne, Inc. Class A?
Currently, no hedge funds are holding shares in BLLN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BillionToOne, Inc. Class A Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$129.50 (-7.23% Downside)
$129.50 (-7.23% Downside)
Blogger Sentiment
Bullish
BLLN Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $944.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.7%
Last 30 Days ▲ 5.4%
Last 30 Days ▲ 5.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Company Description
BillionToOne, Inc. Class A
BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.
BLLN Company Deck
BLLN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive operational and financial performance: very high revenue and volume growth (84% and 44% YoY), expanded ASPs and gross margins (73%), attainment of GAAP profitability and positive cash, major payer wins (Anthem, United), and notable product innovation (Unity Confirm, MRD roadmap). Primary risks noted were margin pressure as oncology scales without Medicare coverage, timing/recognition volatility from true-ups and AR, and multi-year clinical and reimbursement timelines for certain products. On balance, the positives (robust growth, profitability, payer access, new product launches, upgraded guidance, strong cash position) materially outweigh the operational and timing risks cited.View all BLLN earnings summariesBLLN Stock 12 Month Forecast
Average Price Target
$129.50
▼(-7.23% Downside)
Ownership Overview
7.71% Insiders
6.70% Mutual Funds
1.64% Other Institutional Investors
79.52% Public Companies and
Individual Investors